[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cliniques universitaires Saint-Luc- Université Catholique de Louvain\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":618},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,45,68,97,118,145,169,190,216,240,261,283,309,332,355,375,394,426,451,472,496,521,547,569,591],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100520637","epileptogenic-network-visualisation-with-advanced-mri-100520637",false,"NCT06059157","Epileptogenic Network Visualisation With Advanced MRI","EPIVAM","Inclusion Criteria:\n\n* Patient suffering from drug-resistant epilepsy\n* Patient already selected for SEEG implantation as part of their epileptic networks\n\nExclusion Criteria:\n\n* Patient excluded from SEEG (pregnant women, children too young for the procedure, patient unable to undergo the procedure)\n* Contra-indication for MRI","ALL","3 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to improve non-invasive identification of epileptogenic networks in drug-resistant epileptic patient.\n\nThe investigators aim to compare epileptogenic network identification with stereo-EEG (used as glod standard) with the identification of the same network using advanced MRI (rs-fMRI, microstructural analysis of white matter, ...). The main goals are to:\n\n1. Compare the accuracy of network identification.\n2. Analyse the effect of the MRI sequences on candidates selection and target identification.\n\nParticipants will already have been selected for stereoEEG and will undergo a supplementary MRI (about 1h) with the additional MRI sequences. Follow-up MRI are scheduled for patient undergoing a second, therapeutic epileptic surgery.",[27],"Drug Resistant Epilepsy",[29,30,31],"epilepsy","network","non-invasive investigation","RECRUITING","2026-06-11",{"date":35,"type":36},"2026-06-15","ACTUAL",{"date":38,"type":36},"2023-10-25",{"date":40,"type":21},"2029-10",{"name":42,"class":43},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100638774","impact-of-continuous-isotonic-saline-nebulisation-combined-with-heated-humidification-on-the-rheology-of-bronchial-secretions-100638774","NCT07617142","Impact of Continuous Isotonic Saline Nebulisation Combined With Heated Humidification on the Rheology of Bronchial Secretions.","PHYSIORHEO","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Hospitalized in pulmonology unit\n* Excessive airways secretions disease: COPD, Bronchiectassies, Cystic Fibrosis, Primary Ciliary Diskynesia\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Under invasive or non invasive ventilation\n* \\>15L\u002Fmin of oxygen\n* Mucoactive treatment\n* Artificial Upper Airway\n* Respiratory Distress","18 Years",{"count":54,"type":21},35,[24],"This study aims to evaluate whether adding a continuous mist of saltwater (saline nebulization) to warmed, humidified air can improve the properties of mucus in the lungs compared to humidified air alone.\n\nSome patients with chronic lung diseases produce large amounts of thick mucus, which can be difficult to clear and may worsen breathing. Making this mucus easier to move and remove could help improve comfort and breathing.\n\nIn this study, 35 adult patients hospitalized for lung conditions with excessive mucus production will participate. Each patient will receive both treatments on two different days, in a random order:\n\nHeated humidified air alone Heated humidified air combined with continuous saline nebulization This design allows each patient to serve as their own comparison. At the beginning and end of each session, a physiotherapist will help patients clear their airways, and mucus samples will be collected. Each treatment session will last 4 hours.\n\nThe collected mucus will be analyzed in a laboratory to measure how thick, sticky, or elastic it is, and how much force is needed to move it. The main goal is to determine whether the combined treatment makes mucus easier to clear.\n\nThe study will also assess patient comfort, breathing difficulty, ease of clearing mucus, and sleep quality after treatment.\n\nThe results of this study may help improve airway care for patients with chronic lung diseases by identifying more effective ways to manage excessive mucus.",[58],"Excessive Airway Secretions","NOT_YET_RECRUITING","2026-05-29",{"date":62,"type":36},"2026-06-01",{"date":64,"type":21},"2026-05-01",{"date":66,"type":21},"2027-06-30",{"name":42,"class":43},{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":17,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":44},"100530718","does-the-coaching-function-improve-the-learning-of-mechanical-in-exsufflation-mi-e-in-paediatric-subjects-100530718","NCT06190431","Does the Coaching Function Improve the Learning of Mechanical In-exsufflation (MI-E) in Paediatric Subjects?","MI-Ecoaching","Part 1:\n\n* Inclusion criteria\n\n  * Age 6-12 (F\u002FM)\n  * Acceptance of consent (child + 2 parents)\n  * Non-smoker\n  * Speak and understand French\n  * Schooling in mainstream education\n* Exclusion criteria\n\n  * Comorbidities: congenital heart disease, chronic lung disease, immune deficiency, neuromuscular disease, neurological disease or multiple disabilities\n  * History or clinical signs of disease affecting lung function, recent lung infection, spinal or thoracic deformity.\n\nPart 2:\n\n* Inclusion criteria\n\n  * Age 6-12 (F\u002FM)\n  * Acceptance of consent (child + 2 parents)\n  * Non-smoker\n  * Speak and understand French\n  * Patient with a neuromuscular disease\n  * Able to perform the MI-E maneuver\n* Exclusion criteria\n\n  * Hemodynamic instability\n  * Current or recent pneumothorax\n  * Hemoptysis",true,"6 Years","12 Years",{"count":79,"type":21},40,[24],"The use of mechanical insufflation-exsufflation (MI-E) in children with neuromuscular diseases (NMD) is recommended by international guidelines and societies and well documented. Many authors have shown that MI-E is safe and effective for airway clearance and has a significant benefit in reducing the duration of the airway clearance session in children with respiratory infections and atelectasis or in the postoperative period. However, its use in paediatrics is still poorly supervised and learning the technique is too often therapist- and\u002For patient-dependent. The use of a protocol or means of help to guide the initiation and learning of MI-E would allow better use, better adaptation of the settings and potentially better compliance with the treatment. The aim of this study is to test whether the use of a coaching module (playful visual stimulation) in addition to guidance by a physiotherapist improves the learning and effectiveness of the technique compared to guidance alone.This randomized controlled study will first include healthy children, aged 6 to 12 years, with no history or recent respiratory infection affecting lung function or other chronic diseases. In a second phase, the investigators will test the use of the learning process in children with neuromuscular diseases. The investigators hope that the results of this study will provide a better framework for the learning and effectiveness of MI-E. Furthermore, if the results are positive, this will allow better support for the use of MI-E in chronic treatments and help to ensure that this costly treatment for hospitals and public health is used efficiently.",[83,84,85],"Cough","Airway Clearance Impairment","Neuromuscular Diseases",[87,88,89,90],"Mechanical In-Exsufflation","Coaching","Cough Assistance","Pediatric",{"date":62,"type":36},{"date":93,"type":36},"2023-11-20",{"date":95,"type":21},"2026-05-31",{"name":42,"class":43},{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":44},"100640575","treatment-of-acute-low-back-pain-with-transcutaneous-electrical-neurostimulation-in-emergency-departments-100640575","NCT07588490","Treatment of Acute Low Back Pain With Transcutaneous Electrical Neurostimulation in Emergency Departments","Treatment of Acute Low Back Pain With Transcutaneous Electrical Neurostimulation in Emergency Departments: a Randomised Controlled Trial","Inclusion Criteria:\n\n* = or \\> 18 years old\n* pain (EN \\> 3) related to acute lower back pain in the emergency department.\n\nExclusion Criteria:\n\n* Refusal to participate in the study, refusal to sign the informed consent form\n* Consent cannot be obtained (cognitive impairment, language barrier, etc.)\n* Patients with lower back pain lasting more than 6 weeks\n* Taking immediate-release pain medication within the last 6 hours\n* Taking extended-release pain medication within the last 12 hours\n* Taking a muscle relaxant within the last 24 hours\n* Pregnant women\n* Patients requiring immediate medical attention (life-threatening situation)\n* Patient already treated with TENS\n* Patient with a body temperature \\> 38°C\n* Patient with a known spinal infection\n* Lower back pain related to trauma\n* Patient with a known systemic rheumatological or spinal disease\n* Patient with a known systemic inflammatory disease\n* Patient with a known chronic pain condition such as fibromyalgia\n* Patient with pain radiating into the lower limb along the path of one of the following nerves (L3-L4-L5-S1)",{"count":105,"type":21},222,[24],"Acute low back pain is a common reason for emergency department visits (4.39% \\[95% CI: 3.67-5.18\\]). Drug treatment options are limited and largely ineffective. Paracetamol and opioids are no better than placebo for acute low back pain. Only NSAIDs and muscle relaxants have a slightly beneficial effect on pain, but muscle relaxants have an unfavorable benefit-risk ratio.\n\nGiven this situation, it is necessary to explore new non-pharmacological treatment options to relieve the pain of these patients. Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacological therapy that involves applying an electrical current through the skin. Using one or two pairs of electrodes attached to the skin, TENS delivers painless, low-intensity electrical pulses to a painful area or along the path of a nerve.\n\nTENS works by selectively activating large-diameter, non-nociceptive afferent fibers to induce segmental analgesia. In addition, TENS increases the concentration of endorphins in the bloodstream and cerebrospinal fluid.\n\nThe use of TENS has been studied primarily in chronic low back pain. A 2007 Cochrane systematic review concluded that TENS appears to reduce pain and improve range of motion in subjects with chronic low back pain.\n\nThe use of TENS in the emergency department has been little studied. To our knowledge, there are no high-quality studies comparing TENS versus placebo for acute low back pain in patients presenting to an emergency department. This study aims to investigate the analgesic efficacy of TENS compared to placebo in the treatment of acute low back pain in the emergency department.",[109],"Back Pain","2026-05-08",{"date":112,"type":36},"2026-05-14",{"date":114,"type":36},"2026-01-12",{"date":116,"type":21},"2026-12-31",{"name":42,"class":43},{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":17,"minAge":126,"maxAge":52,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100606244","evaluation-of-cardiometabolic-and-auxological-outcomes-of-ghd-patients-under-rhgh-or-lagh-with-stratification-according-to-igf-1-levels-100606244","NCT07173036","Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels","Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under Recombinant Human or Long-acting Growth Hormone With Stratification According to IGF-1 Levels","METAB-BELGROW","Inclusion Criteria:\n\n* Diagnosed with growth hormone deficiency (GHD)\n* Treated with growth hormone (rhGH or LAGH)\n\nExclusion Criteria:\n\n* No exclusion criteria","5 Years",{"count":128,"type":21},300,[24],"The METAB-BELGROW-LAGH study aims to prospectively evaluate the metabolic outcomes of Belgian children diagnosed with growth hormone deficiency (GHD) over a three-year period following the initiation of treatment with either daily recombinant human growth hormone (rhGH) or weekly long-acting growth hormone (LAGH). Patients will be stratified according to their IGF-1 levels. The primary objective is to assess the metabolic outcomes of children treated with daily rhGH over the first three years. The secondary objectives include comparing the metabolic outcomes between patients treated with daily rhGH and those treated with weekly LAGH, and characterizing metabolic profiles based on IGF-1 levels. To achieve these objectives, both standard-of-care (SOC) and additional data will be collected at scheduled follow-up visits (baseline, 6, 12, 24, and 36 months), including clinical, auxological, and biological parameters. Additional metabolic markers, inflammatory and endothelial biomarkers will be assessed. In a subset of patients, carotid intima-media thickness (cIMT) and body fat distribution (via DEXA-scan) will also be measured.",[132],"Growth Hormone Deficiency",[134,135,136,137],"metabolic outcomes","auxological outcomes","recombinant human growth hormone","long acting growth hormone",{"date":139,"type":36},"2026-05-11",{"date":141,"type":21},"2026-07-01",{"date":143,"type":21},"2031-09-01",{"name":42,"class":43},{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":44},"100636152","comparison-of-maintenance-of-propofol-and-sevoflurane-spectral-study-100636152","NCT07561970","COmparison of Maintenance of Propofol And Sevoflurane Spectral Study","Comparison of EEG Power Spectrum During Maintenance of Anesthesia With Propofol Versus Sevoflurane","COMPASS","Inclusion Criteria: Adult patients undergoing elective electrophysiological interventions, such as atrial fibrillation ablation procedures, under general anesthesia\n\n* Capable to give informed consent\n* French-speaking patients\n\nExclusion Criteria:\n\n* Need for a premedication with benzodiazepine before anesthesia\n* Reduced left ventricular ejection fraction (\\\u003C 50%) or underlying cardiac pathology requiring a more balanced anesthesia (administration of benzodiazepine and\u002For ketamine during anesthesia)\n* Preoperative MoCA score \\\u003C 26\u002F30 (for patients \\> ou = 55 years old)\n* Patients treated with anti-epileptic drugs\n* Patients treated with benzodiazepines (ex: for anxiolysis or sleep disorders)\n* Emergencies\n* Morbid obesity (BMI \\> 40kg\u002Fm2)\n* Background of severe postoperative nausea\u002Fvomit",{"count":154,"type":21},280,[24],"Lower EEG alpha band power is currently extensively studied as a potential biomarker of brain vulnerability. No previous study has evaluated whether there was a difference in EEG power spectrum ranges between propofol and sevoflurane, the two main anesthetic agents for maintenance of general anesthesia, in order to define a cut-off value for the prediction of a higher risk of postoperative delirium.\n\n* Primary objective: comparison of EEG alpha power (dB) during maintenance of anesthesia with propofol and sevoflurane using data available in the NeuroSense® depth-of-anesthesia monitoring\n* Secondary objectives: comparison of other EEG frequency bands during maintenance of anesthesia with propofol and sevoflurane using data from the NeuroSense® depth-of-anesthesia monitoring",[158],"Electroencephalography\u002FDrug Effects",[160,161],"intraoperative electroencephalography","alpha-band power","2026-04-24",{"date":64,"type":36},{"date":165,"type":36},"2026-04-13",{"date":167,"type":21},"2027-12",{"name":42,"class":43},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":75,"sex":17,"minAge":52,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":44},"100575727","upper-airway-inflammation-and-olfaction-mechanisms-of-loss-and-recovery-100575727","NCT06776042","Upper Airway Inflammation and Olfaction: Mechanisms of Loss and Recovery","IMMUNODOR","Inclusion Criteria:\n\n* At least two of the following symptoms: nasal obstruction, rhinorrhoea, smell loss, facial pain for 12 weeks.\n* Endoscopic visualisation of bilateral sinonasal polyps\n* SSI (TDI) \\\u003C 30.75 and decreased sense of smell subjectively\n* Eosinophilia \\> 300\u002Fμl of blood Ku\u002Fl\n* On a stable nasal steroid treatment for at least 4 weeks\n\nExclusion Criteria:\n\n* Active smoking\n* Primary and secondary immune deficiencies\n* Ciliary diseases (cystic fibrosis, primary ciliary diskinesia)\n* History of or current nasal malignancies\n* \\\u003C 18 years and \\> 70 years\n* Patients unable to express consent\n* Use of systemic corticosteroids for \\\u003C 4 weeks before visit 1 • Use of systemic or local antibiotics for \\\u003C 4 weeks before visit 1","70 Years",{"count":178,"type":21},140,[24],"The goal of this clinical trial is to understand the mechanisms leading to olfactory dysfunction (OD) in chronic rhinosinusitis (CRS). The main questions it aims to answer are:\n\n* Is the type 2 inflammation impacting the olfactory epithelium regeneration, leading to OD?\n* Does a treatment interfering with one of the major T2 inflammatory cytokines, have an impact on the mechanisms of OD in CRS?\n\nParticipants will undergo olfactory testing and nasal brushing before and after 3 months of treatment.",[182],"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)",{"date":184,"type":36},"2026-04-27",{"date":186,"type":36},"2023-05-22",{"date":188,"type":21},"2026-09-30",{"name":42,"class":43},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":44},"100579702","pocus-impact-on-the-diagnostic-approach-for-thoracic-and-abdominal-pain-in-the-ed-100579702","NCT06827730","PoCUS Impact on the Diagnostic Approach for Thoracic and Abdominal Pain in the ED","DATAPUS","Inclusion Criteria:\n\n* \\> 17 years\n* Thoracic or abdominal pain for less than 72 hours\n* Signed informed consent\n\nExclusion Criteria:\n\n* Reasons making abdominal ultrasound impossible\n* Discovery of a pregnancy during emergency care\n* Follow-up impossible at one month",{"count":198,"type":21},406,[24],"Many medical specialties and paramedical fields are increasingly using point-of-care ultrasound (PoCUS). In daily practice, thoracic and abdominal pain constitute a significant portion of emergency department consultations. PoCUS can be employed in various ways during thoracic and abdominal physical examinations. Most scientific societies advocate for its use to address specific clinical questions rather than to provide a definitive diagnosis.\n\nThe integration of PoCUS into clinical examinations raises the question of its effectiveness in improving the diagnostic approach, rather than its diagnostic accuracy alone. Given the broad spectrum of differential diagnoses for thoracic and abdominal pain, this multicenter prospective study protocol aims to evaluate how PoCUS enhances the diagnostic approach for patients presenting with these symptoms in the emergency department.\n\nTo assess the contribution of PoCUS, three members of an adjudication committee will blindly choose between two case report forms reporting the planned diagnostic approach for each patient: one completed before PoCUS and the other after its use by the investigator handling the case. The hypothesis that PoCUS improves the diagnostic approach by 60% will be reached if 60% of the improved diagnostic approaches favor the case report form filled out after PoCUS.",[202,203],"Abdominal Pain","Thoracic Pain",[205,206,207,208],"thoracic pain","abdominal pain","point of care ultrasound","diagnostic approach",{"date":210,"type":36},"2026-04-30",{"date":212,"type":36},"2025-06-01",{"date":214,"type":21},"2029-06-01",{"name":42,"class":43},{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":44},"100534885","new-relapse-model-in-psychiatry-100534885","NCT06244641","New Relapse Model in Psychiatry","Creation of a Visualization Tool With Integrated Clinical Data to Support Clinical Intervention and Empowerment of Inpatients in Psychiatry : Basis for the Development of a Predictive Model of Relapse","NRMP","Inclusion Criteria:\n\n* To suffer from AUD\n* To be hospitalized\n* To speak French fluently\n* To be able to give their consent (medically and legally).\n\nExclusion Criteria:\n\n* To suffer from severe perceptive disabilities (auditory, visual)\n* To suffer from severe cognitive impairment",{"count":225,"type":21},350,[24],"The goal of this clinical trial is to learn about risk factors of relapse in patients with alcohol use disorder. The main questions it aims to answer are :\n\n* Among patients with Alcohol Use Disorder, are there clusters of patients with the same characteristics and the same outcome ?\n* Which are the risk factors of relapse that are the most predictive ? Do they vary according to cluster?\n* Can a feedback-measurment-system (eg : a feedback of the tests' results) be usefull in a detoxification unit ?\n\nParticipants will :\n\n* Complete auto-questionnaires\n* Pass hetero-evaluations\n* Undergo an electrophysiological battery",[229],"Alcohol Use Disorder",[231,232,233],"clustering","relapse","feedback-measurment-system",{"date":184,"type":36},{"date":236,"type":36},"2024-11-12",{"date":238,"type":21},"2028-02",{"name":42,"class":43},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":75,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":44},"100353931","measurement-of-viscoelastic-properties-of-bronchopulmonary-secretions-100353931","NCT03888300","Measurement of Viscoelastic Properties of Bronchopulmonary Secretions.","VLM-2: Measurement of Viscoelastic Properties of Bronchopulmonary Secretions.","VLM-2","Inclusion Criteria:\n\n* obstructive pulmonary disease\n\nExclusion Criteria:\n\n* none",{"count":249,"type":21},500,[24],"The study is experimental and aims to (a) compare the viscoelastic properties of bronchial secretions obtained in patients suffering from obstructive respiratory disease, and (b) to compare the viscoelastic properties of bronchial secretions obtained in patients before and after application of a respiratory physiotherapy or exercise as usually prescribed.\n\nAfter agreement, the sputum of the participants will be collected according to the method used in clinical routine.Experiments (collection and analysis of sputum) will be conducted at the Saint-Luc University Clinic.",[253],"Obstructive Pulmonary Disease",{"date":255,"type":36},"2026-04-29",{"date":257,"type":36},"2019-08-01",{"date":259,"type":21},"2027-08-01",{"name":42,"class":43},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":75,"sex":17,"minAge":126,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":282},"100250792","motor-and-cognitive-functions-in-acquired-and-developmental-brain-damaged-patients-100250792","NCT02543424","Motor and Cognitive Functions in Acquired and Developmental Brain Damaged Patients","Studies of the Diagnosis, Rehabilitation and Links Between Motor and Cognitive Functions in Acquired and Developmental Brain Damaged Patients","Inclusion Criteria:\n\n* Congenital cerebral palsy and acquired brain injury children and adult patients\n* Presenting upper limb paresis and\u002For hemineglect\n* Between the age of 3 to 90.\n* Able to understand and carry out simple verbal instruction\n\nExclusion Criteria:\n\n* IQ \\\u003C 70\n* Severe aphasia, attentional disorder or psychiatric disorders\n* Neurodegenerative disorders",{"count":269,"type":21},400,[24],"Neurological pathologies cause important and permanent disabilities in every day life. These pathologies can follow stoke, affecting two people per one thousand each year or cerebral palsy, affecting two births per one thousand each year. To date, the diagnosis and the rehabilitation of motor and cognitive problems has been carried out separately by different domains. For example, physiotherapists have focused on motor problems and neuropsychologists have focused on cognitive functions. However, a number of studies have demonstrated a link between motor and cognitive abilities in adults and children. The present study has three main aims: (1) to better evaluate motor and cognitive problems in brain damaged patients (all ages), (2) to understand the link between motor and cognitive abilities in patients and healthy participants and, (3) to propose new types of therapies based on the link between motor and cognitive functions.",[273,274,275],"Cerebral Palsy","Perceptual Disorders","Hemiparesis",{"date":184,"type":36},{"date":278,"type":36},"2015-04",{"date":280,"type":21},"2028-12",{"name":42,"class":43},2,{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":44},"100592022","pseudo-scanner-mri-sequences-for-the-detection-of-bone-lesions-in-multiple-myeloma-100592022","NCT06988020","\"Pseudo-scanner\" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma","Evaluation of Optimised Whole-body MRI Examinations Incorporating \"Pseudo-scanner\" Sequences (ZTE, \"Zero Echo Time\" AND Lava Flex) for the Detection of Bone Lesions in Multiple Myeloma","MM-ZTE-II","Inclusion Criteria:\n\nPatient with newly diagnosed multiple myeloma, for whom bone imaging is required for staging.\n\n* Recurrent patient after intensive treatment (high dose chemotherapy, bone marrow transplant, etc.).\n* Patient requiring a PET \u002F CT considered as the technique of choice in these stages of the disease.\n\nExclusion Criteria:\n\n* Implanted material incompatible with MRI.\n* Severe claustrophobia.\n* Pregnant women",{"count":292,"type":21},45,[24],"Recent work has confirmed the diagnostic performance of pseudo-CT sequences for detecting osteolytic lesions. Their integration into whole body MRI (WB MRI) could transform the diagnostic approach to MM, by allowing a combined assessment of bone marrow involvement, tissue viability and osteolysis, during a single non-irradiating imaging examination. Since the preliminary work mentioned above, optimizations have been made to the pseudo-CT sequences, including the addition of deep learning (correcting noise in the images) and the correction of chemical shift artifact (linked to the coexistence of hydrated tissue and fatty tissue), which carry real hope of improving their diagnostic potential and accuracy.",[296],"Multiple Myeloma Bone Disease",[298,299,300,301],"bone","imaging","mri","multiple myeloma","2026-04-23",{"date":162,"type":36},{"date":305,"type":36},"2025-04-22",{"date":307,"type":21},"2027-11",{"name":42,"class":43},{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":331,"locationsCount":282},"100592021","bone-arches-performance-of-pseudo-scanner-sequences-in-segmenting-the-extent-of-the-tumour-and-in-planning-surgical-resection-using-the-ct-scan-as-a-reference-100592021","NCT06988007","Bone Arches: Performance of Pseudo-scanner Sequences in Segmenting the Extent of the Tumour and in Planning Surgical Resection Using the CT Scan as a Reference","SARCOUPE","Inclusion Criteria:\n\n* diagnosis of bone sarcoma with surgical indication\n\nExclusion Criteria:\n\n* Implanted material incompatible with MRI.\n* Severe claustrophobia.\n* Pregnant women",{"count":317,"type":21},122,[24],"The goal of this exploratory interventional study aims to evaluate the performance of \"pseudo-scanner\" MRI sequences in delineating the tumor extent within bone sarcomas and its ability to serve as a reference for designing cutting guides and enabling \"navigation\" during the surgical procedure, thus exploring the possibility of replacing the scanner to minimize exposure to ionizing radiation in patients with sarcoma.",[321],"Sarcoma",[323,324,325,326],"Imaging","sarcoma","cutting guide","MRI",{"date":255,"type":36},{"date":329,"type":21},"2027-01-01",{"date":167,"type":21},{"name":42,"class":43},{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":340,"minAge":52,"maxAge":341,"enrollmentInfo":342,"targetDuration":4,"studyType":22,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":354,"locationsCount":44},"100553379","mri-pseudo-ct-sequences-for-obstetrical-pelvimetry-100553379","NCT06485323","MRI Pseudo-CT Sequences for Obstetrical Pelvimetry.","MRI Pseudo-CT Sequences for Obstetrical Pelvimetry","Pelvi-MRI","Inclusion Criteria:\n\n* Pregnant woman 33 to 41 week\n* Woman who gave birth by cesarean section, for whom the obstetrician requests a pelvimetry CT for the next pregnancy\n* Pelvimetry planned by the obstetrical team outside of \"emergency\" pathway\n* Adhere to the study protocol after reading the patient information document have signed the informed consent form to participate in the study\n\nExclusion Criteria:\n\n* Usual contraindications to MRI (Pacemaker, Metallic foreign body, Cochlear implant,…)\n* Severe claustrophobia\n* uncomfortable back position","FEMALE","99 Years",{"count":343,"type":21},95,[24],"It is possible to perform a pelvimetry by MRI as a substitute to pelvimetry by CT, hence sparing the patient from a dose of irradiation.",[347],"Obstetric Labor Complications",[349],"technological progress",{"date":255,"type":36},{"date":352,"type":36},"2023-07-05",{"date":116,"type":21},{"name":42,"class":43},{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":22,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":374,"locationsCount":44},"100585050","high-flow-tracheal-therapy-on-tracheobronchial-secretions-in-tracheostomized-patients-100585050","NCT06897319","High-Flow Tracheal Therapy on Tracheobronchial Secretions in Tracheostomized Patients","Impact of High-Flow Tracheal Therapy on the Rheological Properties of Tracheobronchial Secretions in Tracheostomized Patients: A Randomized Crossover Study.","TRACH2O","Inclusion Criteria:\n\n* Adult patients (≥18 years old)\n* Tracheostomized patients\n* Patients requiring routine tracheal suctioning and already using HFT overnight\n\nExclusion Criteria:\n\n* Insufficient secretions for analysis\n* Cognitive impairment or confusion",{"count":364,"type":21},15,[24],"This monocentric, randomized crossover study aims to assess the impact of high-flow tracheal therapy (HFT) on the rheological properties of tracheobronchopulmonary secretions in tracheostomized patients. The primary objective is to compare the viscoelastic characteristics of secretions collected with and without HFT. Secondary objectives include evaluating the effects of HFT on dyspnea, patient comfort, and secretion appearance. The study will take place at Cliniques Universitaires Saint-Luc, with adult tracheostomized patients undergoing standard care.",[368],"Tracheostomized Patients","2026-04-22",{"date":184,"type":36},{"date":372,"type":21},"2026-06-20",{"date":259,"type":21},{"name":42,"class":43},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":384,"phases":4,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":44},"100547754","lung-ultrasound-for-physiotherapy-in-hospitalized-patients-with-respiratory-complications-100547754","NCT06412081","Lung Ultrasound for Physiotherapy in Hospitalized Patients With Respiratory Complications","The Value of Point-of-care Lung Ultrasound for Physiotherapy in Hospitalized Patients With Acute Respiratory Symptoms","Inclusion Criteria:\n\n* Hospitalization in a general ward\n* Acute respiratory symptoms (\\\u003C 48h)\n* Chest X-ray available within 24h before or after the use of LUS\n\nExclusion Criteria:\n\n* Any conditions precluding the use of LUS (thoracic skin lesions, thoracic bandage, subcutaneous emphysema)\n* Inability to understand instructions due to cognitive impairment or due to language barrier",{"count":383,"type":21},30,"OBSERVATIONAL","This study aims to evaluate the relevance of using point-of-care lung ultrasound (LUS) in modifying the physiotherapist's treatment plan for patients hospitalized in a general ward.",[387],"Respiratory Complication",{"date":184,"type":36},{"date":390,"type":36},"2024-05-10",{"date":392,"type":21},"2026-12-30",{"name":42,"class":43},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":402,"minAge":52,"maxAge":403,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":406,"briefSummary":407,"conditions":408,"keywords":412,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":44},"100634664","fertility-restoration-with-autografting-of-cryopreserved-immature-testicular-tissue-100634664","NCT07542626","Fertility Restoration With Autografting of Cryopreserved Immature Testicular Tissue","Fertility Restoration With Autotransplantation of Cryopreserved Immature Testicular Tissue (ITT) Restaurer la fertilité à Partir de Tissu Testiculaire Immature (TTI) cryopréservé Par Auto-transplantation du Tissu","TESTIGRAFT","Inclusion Criteria: all are required\n\n* patients who have completed their gonadotoxic treatment\n* patients who are in good health after care of the primary disease based on hemato-oncologist input\n* patients with proven azoospermia in adulthood and child's wish requesting transplantation\n* patients who cryopreserved and stored their immature testicular tissue (in conformity with regulatory requirements)\n* in case of prior hematological malignant disease or metatstatic cancer, if the multidisciplinary assesment considers the risk of cancer cell contamination is negligible\n\nExclusion Criteria:\n\n* patients for whom the cryostored tissue presents a non-negligible risk of cancer cells contamination\n* patients presenting with a contraindication for general anethesia","MALE","40 Years",{"count":405,"type":21},20,[24],"This is a pilot clinical trial to evaluate the feasibility and outcome of autologous transplantation of immature testicular tissue cryopreserved during childhood as a method of fertility preservation for prepubertal boys in case of gonadotoxic therapies.\n\nFreezing of immature testicular tissue is performed since the early 2000s and a number of our patients have now reached reproductive age. In case of childwish and azoospermia in adulthood, surgical sperm retrieval is planned and if unsucessful transplantation of the patient's own cryopreserved tissue will be performed during the same surgical intervention as a fertility restoration method.",[409,410,411],"Azoospermia or Severe Oligozoospermia","Infertility","Autologous Transplantation",[413,414,415,416,417],"autotransplantation of immature testicular tissue","fertility preservation","prepubertal boys","cryopreserved testicular tissue","prepubertal testicular tissue","2026-04-17",{"date":420,"type":36},"2026-04-21",{"date":422,"type":36},"2025-11-19",{"date":424,"type":21},"2037-11",{"name":42,"class":43},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":22,"phases":435,"briefSummary":436,"conditions":437,"keywords":439,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":448,"leadSponsor":450,"locationsCount":44},"100628691","new-tools-and-predictive-markers-in-the-prognosis-of-hypoxic-ischemic-encephalopathy-following-cardiac-arrest-100628691","NCT07464938","New Tools and Predictive Markers in the Prognosis of Hypoxic-ischemic Encephalopathy Following Cardiac Arrest","ARCAPROTEOFLOW","Inclusion Criteria:\n\n* Patients 18-year-old with OHCA admitted to our hospital receiving routine care.\n\nExclusion Criteria:\n\n* Patients transferred from other hospitals for OHCA management\n* Patients with pre-existent neurological disease.",{"count":434,"type":21},50,[24],"Cardiac arrest (CA) remains a major cause of mortality and long-term neurological disability worldwide. Despite advances in resuscitation, many survivors suffer from post-cardiac syndrome encompassing PCAS brain injury (PCABI), due to primary (ischemic) and secondary (reperfusion) injury, myocardial dysfunction, systemic response, and persistent underlying causes. PCABI plays a critical role in this complex condition, which is characterized by ischemia, inflammation, and microvascular dysfunction.Current methods to predict neurological outcomes are limited, leading to challenges in clinical decision-making and the risk of premature withdrawal of life-sustaining therapies. This study aims to improve prognostication in CA patients by integrating advanced serum biomarker profiling with cerebral ultrasound (CU) techniques. The investigators hypothesize that combining these tools with clinical data will enhance the accuracy of neurological outcome predictions and deepen understanding of PCABI pathophysiology. The investigators will prospectively enroll 50 CA patients admitted to the intensive care unit at Cliniques Universitaires Saint-Luc. Serum proteomics will be performed using the Reveal panel from Olink®, which analyzes over 1,000 proteins involved in inflammation and thrombosis implicated in PCABI. Concurrently, cerebral ultrasound will assess optic nerve sheath diameter (ONSD) and cerebral blood flow velocities (CBFV) at multiple time points post-resuscitation (at admission, on day 1-2 and on day 3-5). These non-invasive bedside measurements may serve as early indicators of elevated intracranial pressure and cerebral hemodynamic abnormalities.The primary endpoint is poor neurological outcome at one month, defined by the Cerebral Performance Category (CPC) scale. Statistical analyses will evaluate the prognostic value of biomarkers and ultrasound parameters individually and in combination with established clinical predictors.This multimodal approach promises to refine prognostic accuracy, improve clinical decision-making, and identify novel therapeutic targets. Ultimately, our findings may lead to improved patient outcomes and guide future multicenter studies for validation and clinical implementation.",[438],"Cardiac Arrest (CA)",[440,441,442,443],"cardiac arrest","proteomic","Cerebral ultrasounds","neuroprognostication","2026-03-23",{"date":446,"type":36},"2026-03-27",{"date":444,"type":36},{"date":449,"type":21},"2028-04-01",{"name":42,"class":43},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":402,"minAge":52,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":22,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":44},"100611835","prospective-clinical-study-comparing-proms-after-adaptive-or-conventional-radiotherapy-in-prostate-cancer-100611835","NCT07245745","Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer","Prospective Clinical Study Comparing Patient-reported Outcomes Measurements (PROMS) After Adaptive or Conventional Radiotherapy in Prostate Cancer","Inclusion Criteria:\n\n* Patients with prostate cancer referred for curative-intent radiotherapy\n* Male patients ≥ 18 years old\n* ECOG performance status 0-1\n* Patients willing to use an e-health application\n* Patients capable of using an e-health application\n* Proficient in French, English, or Dutch\n* No prior history of treatment for rectal or bladder cancer\n* No prior history of pelvic radiotherapy\n\nExclusion Criteria:\n\n* Cognitive impairment\n* ECOG ≥ 2\n* History of treatment for rectal or bladder cancer\n* History of pelvic radiotherapy\n* No access to the Noona application on a smartphone or computer",{"count":459,"type":21},188,[24],"This prospective clinical study compares patient-reported outcome measures (PROMs) after adaptive or conventional radiotherapy in prostate cancer. Adaptive radiotherapy (ART) aims to reduce uncertainties related to daily anatomical variations, thereby improving treatment accuracy while decreasing gastrointestinal (GI) and genitourinary (GU) toxicity. This study, conducted at Cliniques universitaires Saint-Luc (Brussels and Ottignies sites), analyzes and compares toxicities in patients treated with ART on Ethos and those treated with conventional radiotherapy on Halcyon.\n\nThe primary objective of the study is to demonstrate that ART reduces gastrointestinal, urinary, and general side effects induced by radiotherapy. Additionally, the secondary objectives include assessing the duration of these effects, correlating them with dosimetric data, analyzing the management of toxicities through the Noona e-health application, as well as evaluating the use of this application by both patients and healthcare providers.\n\nThe study includes men aged 18 years or older with prostate cancer undergoing curative-intent treatment, with an ECOG performance status of 0 to 1, and able to use the Noona application. Patients with a history of rectal or bladder treatment, or those who have already received pelvic radiotherapy, are excluded. Two groups are compared: patients treated with conventional radiotherapy on Halcyon (Ottignies site) and those treated with adaptive radiotherapy on Ethos (Brussels site).",[463],"Prostate Cancer","2026-03-12",{"date":466,"type":36},"2026-03-16",{"date":468,"type":36},"2026-01-13",{"date":470,"type":21},"2029-03-31",{"name":42,"class":43},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":495},"100571375","achieving-a-better-outcome-through-limiting-the-glioblastoma-clinical-target-volume-100571375","NCT06719440","Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume","Impact of Reducing the Irradiation Volume on Survival, Toxicity, and Quality of Life in Patients With Glioblastoma Treated With Radiochemotherapy: a Prospective Multicenter Randomised Study","BELGICA","Inclusion Criteria:\n\n* Participants capable of giving informed consent\n* Age \\>= 18 y.o.\n* WHO performance status 0-2\n* Newly diagnosed glioblastoma (Histologically proven glioblastoma per WHO 2021 classification based on biopsy or resection )\n* Indication of chemoradiotherapy confirmed by multidisciplinary tumour board\n\nExclusion Criteria:\n\n* Participation in a competing trial\n* Known contraindication to undergo MRI scans",{"count":481,"type":21},347,[24],"The objective of the BELGICA trial is to evaluate if radiotherapy could be given in a more focused manner in patients with glioblastoma in order to reduce side effects and improve quality of life.\n\nThe glioblastoma (GBM) is the most common and aggressive tumour originating from the brain, affecting approximately 600 patients per year in Belgium. The treatment consists in surgical resection of the tumour (when feasible), followed by a combination of radiotherapy and chemotherapy. Despite multimodal treatment (surgery, radiotherapy, and chemotherapy), the life expectancy of patients with GBM remains limited, with an average survival of 12-18 months and only 5% of patients surviving more than 5 years. In addition to limited survival, most patients with GBM experience impaired quality of life, both because of the disease and treatments.\n\nRadiotherapy is a treatment where radiation is used to kill cancer cells. In GBM, radiotherapy is targeted at the tumour (or tumour bed if the tumour was resected) with a safety margin around it (the \"Clinical Target Volume\" or CTV) to account for potential microscopic spread of the tumour. The downside of this safety margin is that a substantial amount of brain tissue is irradiated, which can lead to treatment toxicity. Reducing the CTV margin would enable to decrease the volume of brain being irradiated and could thereby allow to reduce the side effects of brain irradiation.\n\nThe BELGICA trial (Achieving a BEtter outcome through Limiting the GlIoblastoma Clinical tArget volume) is a national multicentre trial which will evaluate if reducing the irradiation volume in glioblastoma is safe and allows for lowering side effects and improving quality of life.",[485,486],"Glioblastoma","Radiotherapy Side Effect","2026-02-24",{"date":489,"type":36},"2026-02-27",{"date":491,"type":36},"2025-05-12",{"date":493,"type":21},"2031-10",{"name":42,"class":43},23,{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":22,"phases":504,"briefSummary":505,"conditions":506,"keywords":508,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":44},"100617849","feasibility-of-mask-free-radiotherapy-for-brain-tumor-patients-100617849","NCT07323966","Feasibility of Mask-Free Radiotherapy for Brain Tumor Patients","MASKLESS","Inclusion Criteria:\n\n* Age \\>= 18 years old\n* Brain tumor treated with fractionated radiotherapy\n* Able to read and complete a questionnaire in French\n\nExclusion Criteria:\n\n* Inability to remain still",{"count":405,"type":21},[24],"The aim of this study is to investigate the technical feasibility of brain radiotherapy without immobilization masks using surface imaging to ensure accurate patient positioning and continuous motion monitoring.",[507],"Brain Tumor",[509,510,511,512],"radiotherapy","brain tumor","mask","surface guidance","2025-12-22",{"date":515,"type":36},"2026-01-07",{"date":517,"type":36},"2025-11-18",{"date":519,"type":21},"2026-06-30",{"name":42,"class":43},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":528,"enrollmentInfo":529,"targetDuration":4,"studyType":22,"phases":530,"briefSummary":531,"conditions":532,"keywords":536,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":4},"100605338","implementation-of-new-exercise-protocols-in-cardiac-rehabilitation-100605338","NCT07161219","Implementation of New Exercise Protocols in Cardiac Rehabilitation.","REVACARD","Inclusion Criteria:\n\n\\- Patient meeting the conditions of the permanent life support agreement following hospitalization for a cardiac condition such as: acute myocardial infarction; coronary surgery; therapeutic percutaneous endovascular intervention on the coronary arteries, under medical imaging guidance; therapeutic percutaneous endovascular intervention on the heart, under medical imaging guidance; surgery for congenital or acquired heart malformation; surgery for valvular lesion; heart transplantation; resistant angina (to be specified by detailed history, medical history, and technical examinations, justifying multidisciplinary care); cardiomyopathy with left ventricular dysfunction (to be specified by detailed history, medical history, and technical examinations, justifying multidisciplinary care).\n\n* Patient aged between 18 and 80 years.\n* Patient capable of giving informed consent.\n* Patient registered for permanent life support at the CuSL.\n* Patient capable of understanding instructions in French. - Patient with prior medical consent and clinically stable.\n\nExclusion Criteria:\n\n* \\- Minor (\\\u003C18 years old).\n* Pregnant woman.\n* Patient unable to provide informed consent.\n* Patient with cognitive, neurological, or orthopedic limitations.\n* Patient with mobility or musculoskeletal difficulties incompatible with physical activity.\n* Clinical instability.","80 Years",{"count":20,"type":21},[24],"* Primary Objective: To evaluate the effects of complementary exercise protocols in cardiac rehabilitation (CR), such as inspiratory muscle training (IMT), by assessing inspiratory muscle strength.\n* Secondary Objectives: To assess functional capacity, quality of life (QoL), and pulmonary function.",[533,534,535],"Heart Diseases","Cardiac Disease","Inspiratory Muscle Training",[537,538],"heart failure","inspiratory muscles training","2025-09-18",{"date":541,"type":36},"2025-09-23",{"date":543,"type":21},"2025-12-01",{"date":545,"type":21},"2029-12-31",{"name":42,"class":43},{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":22,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":4},"100607024","treatment-of-acute-low-back-pain-with-transcutaneous-electrical-neurostimulation-at-the-emergency-department-a-randomized-controlled-trial-100607024","NCT07183176","Treatment of Acute Low Back Pain With Transcutaneous Electrical Neurostimulation at the Emergency Department: a Randomized Controlled Trial","TENS BACK PAIN","Inclusion Criteria:\n\n* All patients admitted to the emergency department and aged over 18 years with pain (EN \\> 3) related to acute low back pain.\n\nThe lumbar region is defined as the anatomical area between the costal margin and the gluteal fold.\n\nAcute low back pain is defined by the World Health Organisation, and by part of the literature, as a low back pain that appeared less than 6 weeks ago.\n\nExclusion Criteria:\n\nRefusal to participate in study, refusal to sign informed consent\n\n* Consent is impossible to obtain (cognitive impairment, language barrier, etc.)\n* Patients with low back pain lasting more than \\> 6 weeks\n* Pregnant women\n* Patient requiring immediate medical attention (vital distress).\n* Patient already treated with a TENS\n* Patient with a body temperature \\> 38°C\n* Patient known to have a spinal infection\n* Lumbar pain linked to trauma\n* Patient with known systemic or spinal rheumatological disease\n* Patient with a known systemic inflammatory disease\n* A patient with a known chronic pain condition such as fibromyalgia\n* Patient with pain radiating into the lower limb along the course of one of the following nerves (L3-L4-L5- S1)",{"count":555,"type":21},250,[24],"Acute low back pain is a frequent cause of emergency department admissions (4.39% \\[95% CI: 3.67-5.18\\])1. Drug therapeutic options are limited and ineffective. Paracetamol and opioids are no better than placebo for acute low-back pain 2,3. Only NSAIDs and muscle relaxants have a slightly beneficial effect on pain, but muscle relaxants have an unfavorable risk-benefit balance.2 In this situation, it is necessary to turn to new non-drug therapeutic options to relieve pain of these patients. Transcutaneous electrical nerve stimulation (TENS) is a non-drug therapy that involves applying an electrical current through the skin. Through one or two pairs of electrodes stuck to the skin, TENS delivers painless, low-intensity electrical impulses to a painful area or a nerve pathway.\n\nTENS acts by selectively activating large-diameter non-nociceptive afferent fibers to induce segmental analgesia4. In addition, TENS increases the concentration of endorphins in the bloodstream and cerebrospinal fluid5.\n\nThe use of TENS has been studied mainly in chronic low-back pain. A 2007 Cochrane systematic review concluded that TENS appears to reduce pain and improve range of motion for subjects with chronic low back pain6.\n\nThe use of TENS in emergency departments has been little studied. A 2018 pilot study of 110 patients admitted to the emergency department with acute or chronic pain observed a reduction in pain (from an average of 8.50 on the numerical pain scale \\[EN\\] \\[7.52 - 9.48\\] to 4.67 \\[3.51 - 5.89\\]) after TENS use and functional improvement in 83% of patients7.\n\nThe Gulacti study, carried out in 2022, investigated the use of TENS to treat pain of patients admitted to the emergency department with a renal colic attack : the mean reduction in VAS score at 15 and 30 minutes was significantly greater for the TENS group than for the placebo group (mean reduction in VAS score at 15 minutes was 33.3 ± 17.6 (95% CI : 28.3 to 38.3) for the TENS group and 14.9 ± 11.6 (95% CI: 11.6 to 18.2) for the placebo group \\[mean difference: 18.4 (95% CI: 12.5 to 24.4, P \\\u003C 0.0001)\\]. The mean reduction in VAS score after 30 minutes was 63.7 ± 21.1 (95% CI: 57.7 to 69.7) for the TENS group and 14.9 ± 16.2 (95% CI: 19.5 to 10.3) for the placebo group (mean difference: 48.8, 95% CI: 41.4 to 56.3, P \\\u003C 0.0001)8.\n\nA single study of 76 patients focused on acute low-back pain during patient transport to emergency departments. The authors recorded a significant reduction (p= 0.01) in pain during transport of the TENS group (79.2 ± 6.5 mm VAS to 48.9 ± 8.2 0 mm VAS), while pain scores remained unchanged for the placebo group (75.9 ± 16.4 mm VAS and 77.1 ± 11.2 mm VAS)9.\n\nTo our knowledge, there is no high-quality study of TENS versus placebo for acute low back pain of patients admitted to an emergency department.\n\n1. Primary objective:\n\n   Study the analgesic efficacy of TENS compared to placebo in the treatment of acute low back pain at the emergency department.\n2. Secondary objective:\n\n1\\. Compare the number of patients who will show a \\> 50% reduction of their initial pain.\n\n2\\. Compare the number of patients requiring rescue treatment. 3. Compare the occurrence of side effects among groups. 4. Compare patient satisfaction after 30 minutes. 5. Compare patient comfort level after 30 minutes.\n\nMain criterion:\n\nComparison of the proportion of patients with \\>30% reduction of initial pain after 30 minutes of treatment\n\nSecondary criterion:\n\n1. Proportion of patients with \\> 50% reduction of their initial pain after 30 minutes of treatment.\n2. Proportion of patients requiring morphine titration for pain relief.\n3. The rate of side-effects associated with the use of TENS.\n4. The level of satisfaction measured by numerical satisfaction scale ranging from 0 (not at all satisfied) to 10 (extremely satisfied) EN. A patient will be considered very satisfied if he\u002Fshe presents a satisfaction level ≥ 8.\n5. The level of comfort will be assessed by a comfort scale ranging from 0 (not at all comfortable) to 10 (very comfortable patient).",[559,560],"Acute Back Pain","Emergency Department Patient","2025-09-12",{"date":563,"type":36},"2025-09-19",{"date":565,"type":21},"2025-09-15",{"date":567,"type":21},"2026-09-15",{"name":42,"class":43},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":75,"sex":17,"minAge":52,"maxAge":576,"enrollmentInfo":577,"targetDuration":4,"studyType":22,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":44},"100539480","effect-of-blue-light-on-vagus-nerve-stimulation-in-patients-with-refractory-epilepsy-100539480","NCT06304389","Effect of Blue Light on Vagus Nerve Stimulation in Patients With Refractory Epilepsy","BLUELIGHTVNS","Inclusion Criteria:\n\nPatients:\n\nVNS implanted since at least 3 months age \\>18-60 years; IQ \\>55 on Wechsler scale (normal status or mild cognitive impairment)\n\nhealthy participants aged between 18 and 35 years without any medical history (neurological \u002F psychiatric disease)\n\nExclusion criteria:\n\nPatients:\n\nother medical implanted devices than VNS, ocular diseases\n\nHelthy participants:\n\nmedical implanted devices, cerebral trauma, ocular disease","60 Years",{"count":578,"type":21},34,[24],"Vagus nerve stimulation (VNS) is an adjunctive treatment for refractory epilepsy. Although widely used, there is still a substantial number of patients with insufficient response. Light, and particularly blue light, can stimulate alertness, attention and cognition through modulation of anatomical targets which are common to the vagal afferent network. This project aims at understanding how exposure to blue enriched light may influence VNS effects in patients with refractory epilepsy by exploring the modulation of a series of biomarkers of VNS action. This could possibly lead to new therapeutic strategies to increase efficacy of VNS.",[582],"Refractory Epilepsy","2025-09-03",{"date":585,"type":36},"2025-09-10",{"date":587,"type":36},"2023-07-01",{"date":589,"type":21},"2026-04",{"name":42,"class":43},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":340,"minAge":52,"maxAge":599,"enrollmentInfo":600,"targetDuration":4,"studyType":22,"phases":602,"briefSummary":603,"conditions":604,"keywords":606,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":4},"100600970","virtual-reality-hypnosis-as-sedation-during-oocyte-retrieval-effect-on-propofol-consumption-100600970","NCT07104409","Virtual Reality Hypnosis as Sedation During Oocyte Retrieval: Effect on Propofol Consumption","Virtual Reality Hypnosis as Sedation During Oocyte Retrieval: Effect on Propofol Consumption: a Randomized Study (VRH-IVF)","VRH-IVF","Inclusion Criteria:\n\n* egg retrieval as part of their IVF at the Cliniques universitaires Saint-Luc,\n* to be French-speaking,\n* simple IVF or ICSI IVF\n* 18-42 yrs\n\nExclusion Criteria:\n\n* morbid obesity\n* blindness and\u002For deafness\n* history contraindicating the use of anti-inflammatory drugs\n* long-term psychotherapeutic treatment or taking psychotropic medications.","42 Years",{"count":601,"type":21},72,[24],"An egg retrieval is performed during an IVF course. This painful procedure is performed using sedation to ensure patient comfort. A combination of sedative and analgesic medications combined with local anesthesia (paracervical block) is used. Propofol, the intravenous anesthetic of choice (rapid-acting and short-acting), and remifentanil (an ultra-short-acting opioid analgesic) are generally combined. The potential impact of these agents used for egg retrieval on egg fertilization and embryo quality is of interest. Indeed, certain drugs such as propofol could accumulate in the follicular fluid. The few studies conducted to date show contradictory results. While a harmful effect appears to be reported in experimental studies on mice, this effect is uncertain in clinical studies. Given this uncertainty, any method aimed at reducing propofol consumption in this context may be of interest. Virtual reality hypnosis (VRH) is a digital tool that has already been shown to be effective in reducing preoperative anxiety during oocyte retrieval. Furthermore, VRH has also demonstrated analgesic effects.\n\nThe primary objective of this study is to compare VRH with a control group (usual sedation) on propofol consumption during oocyte retrieval.\n\nSecondary objectives are to compare preoperative anxiety, APAIS score, catastrophizing score, remifentanil consumption, intra- and\u002For post-operative nausea and vomiting, post-procedural analgesic consumption, time perception during the procedure, fertilization parameters, and pregnancy rate at 12 weeks. The degrees of absorption, dissociation, immersion, and presence for the VRH group will also be noted.",[605],"Oocyte Retrieval for IVF",[607,608,609],"virtual reality","hypnosis","oocyte retrieval","2025-08-05",{"date":612,"type":36},"2025-08-11",{"date":614,"type":21},"2025-09-01",{"date":616,"type":21},"2027-02-01",{"name":42,"class":43},""]